On Nov 01, major Wall Street analysts update their ratings for $Eli Lilly and Co (LLY.US)$, with price targets ranging from $970 to $1,146.
Morgan Stanley analyst Terence Flynn maintains with a buy rating, and adjusts the target price from $1,158 to $1,146.
BofA Securities analyst Alec Stranahan maintains with a buy rating, and adjusts the target price from $1,150 to $1,100.
Barclays analyst Carter Gould maintains with a buy rating, and adjusts the target price from $1,025 to $975.
Jefferies analyst Akash Tewari maintains with a buy rating, and adjusts the target price from $1,113 to $994.
Truist Financial analyst Srikripa Devarakonda maintains with a buy rating, and adjusts the target price from $1,033 to $1,029.
Furthermore, according to the comprehensive report, the opinions of $Eli Lilly and Co (LLY.US)$'s main analysts recently are as follows:
Eli Lilly's recent quarter revealed uneven results for Mounjaro and Zepbound, which were clarified as being connected to inventory dynamics rather than supply or demand factors. Despite a slight reduction in expectations for Mounjaro and Zepbound, the overall outlook on Eli Lilly remains optimistic, even considering the third-quarter irregularities.
Post the Q3 report, Eli Lilly's forecast suggests there is 'substantial work' ahead for Q4, given the tirzepatide miss, fluctuating channel inventories, and the delay of direct-to-consumer activities until mid-quarter.
Here are the latest investment ratings and price targets for $Eli Lilly and Co (LLY.US)$ from 6 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间11月1日，多家华尔街大行更新了$礼来 (LLY.US)$的评级，目标价介于970美元至1,146美元。
摩根士丹利分析师Terence Flynn维持买入评级，并将目标价从1,158美元下调至1,146美元。
美银证券分析师Alec Stranahan维持买入评级，并将目标价从1,150美元下调至1,100美元。
巴克莱银行分析师Carter Gould维持买入评级，并将目标价从1,025美元下调至975美元。
富瑞集团分析师Akash Tewari维持买入评级，并将目标价从1,113美元下调至994美元。
储亿银行分析师Srikripa Devarakonda维持买入评级，并将目标价从1,033美元下调至1,029美元。
此外，综合报道，$礼来 (LLY.US)$近期主要分析师观点如下：
Eli Lilly最近的季度显示，Mounjaro和Zepbound的结果不稳定，这与库存动态有关，而不是供应或需求因素。尽管对Mounjaro和Zepbound的预期有所降低，但对Eli Lilly的整体展望仍然乐观，甚至考虑到第三季度的不规则性。
发帖Q3报告后，Eli Lilly的预测表明Q4还有"大量工作"要做，考虑到tirzepatide的遗漏、波动的渠道库存以及直接面向消费者的活动推迟到中旬。
以下为今日6位分析师对$礼来 (LLY.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
